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Abstract.  The major excreted protein (MEP) of trans- 
formed mouse fibroblasts is the lysosomal protease, 
cathepsin L. MEP is also secreted by untransformed 
mouse cells in response to growth factors and tumor 
promoters, and is thought to play a  role in cell growth 
and transformation. To determine the relationship be- 
tween MEP synthesis and MEP secretion, we have ex- 
amined these events in PDGF-treated NIH 3T3 cells. 
PDGF enhanced MEP synthesis and caused the diver- 
sion of MEP from the lysosomal delivery pathway to a 
secretory pathway. These two effects were found to be 
regulated independently at various times after growth 
factor addition. Short PDGF treatments (0.5 or  1 h) 
resulted in quantitative secretion of MEP although 
synthesis was near the control level. High levels of 
both synthesis and secretion occurred between 2  and 
14 h  of PDGF treatment. Between  18 and 30 h, the 
amount of secreted MEP returned to the low control 
level even though synthesis remained elevated. The 
secretion was specific for MEP; other lysosomal en- 
zymes were not found in the media from PDGF- 
treated cells. PDGF-induced secretion of MEP was in- 
hibited 84%  by cycloheximide, suggesting that protein 
synthesis is required to elicit this effect. PDGF also 
caused  a  time-dependent increase  in  mannose 6-phos- 
phate (Man-6-P)  receptor-mediated endocytosis. 
These data support a  model in which PDGF alters the 
distribution of Man-6-P receptors such that the Golgi 
concentration of receptors becomes limiting, thereby 
causing the selective secretion of the low affinity 
ligand, MEP. 
V 
I  R  A  L transformation of fibroblasts causes major qual- 
itative and quantitative alterations in protein synthe- 
sis and degradation that are responsible for the in- 
creased growth rate observed in transformed cells. Enhanced 
secretion of a number of lysosomal hydrolases has been ob- 
served in response to transforming and growth-promoting 
agents, and the secreted enzymes are thought to function in 
the processes of normal and tumor cell growth and tumor 
metastasis (2, 9,  14, 32, 34, 42, 43, 46). 
An example of a lysosomal enzyme that may play an ex- 
tracellular role during cell growth is the major excreted pro- 
tein  (MEP) I of transformed mouse  NIH  3T3  fibroblasts, 
which has been identified as cathepsin L (7,  14,  15, 26, 27, 
35, 44). This cysteine protease is localized in lysosomes in 
resting,  untransformed NIH  3T3  cells (11, 16). However, 
in rapidly growing transformed cells, MEP is synthesized in 
large quantities and secreted (11, 17, 18). High levels of MEP 
are  also  secreted  by  untransformed cells  in  response  to 
growth  promoting  agents  such  as  PDGF  and  epidermal 
growth factor or tumor-promoting phorbol esters (3,  10, 13, 
18, 41). Although direct evidence is lacking, these results 
suggest that secreted MEP plays some role in the growth of 
normal and transformed cells. 
In resting NIH 3T3 cells, MEP is synthesized as a 39,000- 
1. Abbreviations used in this paper: Man-6-P, mannose 6-phosphate; MEE 
major excreted protein. 
Mr precursor that is processed intracellularly in two steps to 
a 20,000-Mr mature lysosomal form (16). It is the precursor 
form of MEP that is secreted in response to growth-promot- 
ing agents.  The 39,000-Mr form of MEP contains mannose 
6-phosphate (Man-6-P),  the characteristic marker of most 
lysosomal hydrolases, and binds to Man-6-P receptors (38), 
the receptors responsible for efficient delivery of most lyso- 
somal enzymes to lysosomes. 
MEP made by resting cells appears to follow the same in- 
tracellular route as do other lysosomal enzymes (for review, 
see references 6, 12, 21, 31, 37, 47). Lysosomal enzymes are 
synthesized in the endoplasmic reticulum, and then trans- 
ported to the Golgi apparatus where their oligosaccharide 
side chains are modified to contain Man-6-P.  The enzymes 
are  segregated from other glycoproteins upon binding to 
Man-6-P receptors present in the trans Golgi apparatus. The 
enzyme-receptor complexes are  transported to  a  prelyso- 
somal compartment where they dissociate, and the enzymes 
are delivered to lysosomes, while the receptors are recycled. 
The  270,000-Mr  cation-independent  Man-6-P  receptor  is 
thought to be primarily responsible for normal transport and 
delivery of lysosomal enzymes in most cells and tissues. 
However,  the discovery of a second Man-6-P receptor, the 
46,000-M~ cation-dependent receptor (20),  suggests that at 
least one other system for lysosomal enzyme delivery may 
exist. 
The diversion of MEP from the normal lysosomal delivery 
pathway in rapidly growing cells, even though it possesses 
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be regulated.  We have been studying the mechanisms  re- 
sponsible for enhanced secretion of MEP by transformed 
cells and  growth factor-treated untransformed cells.  In  a 
previous report,  we  showed  that  secretion of MEP  by a 
virally transformed NIH 3T3 cell line is specific (i.e., other 
lysosomal enzymes are not secreted), and that MEP synthe- 
sized by normal and transformed cells has a  much lower 
affinity for the cation-independent Man-6-P receptor than do 
other lysosomal enzymes (11). 
To further characterize the relationship between MEP syn- 
thesis and secretion, we have examined these phenomena in 
growth factor-treated, untransformed fibroblasts. This study 
characterizes the time-dependent increases in both synthesis 
and secretion of MEP and shows that these two processes are 
regulated independently. We also present evidence that in- 
creased secretion of MEP is a result of a growth factor-in- 
duced alteration in the lysosomal protein transport system. 
Materials and Methods 
Materials 
Recombinant platelet-derived growth factor (c-sis) was obtained from Am- 
gen Biologicals (Thousand Oaks, CA). Immunoprecipitin (a 10% cell sus- 
pension of fixed, protein A-containing Staphylococcus  aureus  cells) was 
from Bethesda Research Laboratories (Gaithersburg, MD).  [3~S]Methio- 
nine (Tran35S-label) was from ICN Radiochemicals (Irvine, CA). Antibod- 
ies  directed against MEP  (MP-1)  and  the cation-independent Man-6-P 
receptor (GS-6) were raised in New Zealand White rabbits as previously de- 
scribed (39). Cation-iodependent Man-6-P receptor was purified from bo- 
vine liver (38). Antisera against proliferin (23) and mitogen-regulated pro- 
tein (29)  were gifts from S.  J.  Lee and  D.  Nathans of Johns  Hopkins 
University and Marit Nilsen-Hamilton and Richard Hamilton of the Univer- 
sity of Iowa, respectively. ~Galactosidase was purified from bovine testes 
as previously described (8), and radio-iodinated using BoRon-Hunter re- 
agent (39) that was purchased from ICN Radiochemicals. 
Cell Culture and Growth Factor Treatments 
NIH 3T3 mouse fibroblasts were routinely grown in DME, supplemented 
with 10% calf serum (Gibco Laboratories, Grand Island, NY), at 37°C in 
a humidified atmosphere of 5 % CO2.  Density-arrested cells were obtained 
by plating cells in 24-well cluster plates (Costar, Cambridge, MA) or 60- 
mm plates (Falcon Labware, Becton, Dickinson &  Co., Oxnard, CA) in 
DME with 10% calf serum, and growing them for 5 d without any change 
of the medium. Arrested growth was verified by [3H]thymidine incorpora- 
tion assays, as previously described (28). 
The density-arrested cells were treated with PDGF (final concentration, 
15 ng/ml) in fresh serum-free DME containing 10 ng/ml transferrin (Sigma 
Chemical Company, St.  Louis, MO) and 4  nM  sodium selenite (Gibco 
Laboratories). Times and other details of the growth factor treatments are 
described in the figure legends. The experiments were standardized accord- 
ing to the number of cells present at the beginning of the treatments. In most 
cases, this number remained constant throughout the course of the experi- 
ment. The exception was a slight loss of untreated cells during the labeling 
and chase periods in serum-free medium. This problem has since been 
solved by the addition of 1 mg/ml BSA to the labeling medium. There was 
no loss of PDGF-treated cells either in the absence or presence of BSA. 
[JsS]Methionine-labeling and lmmunoprecipitation 
of MEP 
Cells in 24-well  plates were labeled with [35S]methionine  (100-200/~Ci/ 
ml) in 0.5 ml serum-free DME containing 3 nM unlabeled methionine, 10 
ng/ml transferrin, and 4 nM sodium selenite, for the times indicated in the 
figure legends. For pulse-chase studies, the label was "chased" with 200 nM 
unlabeled methionine. At the end of the labeling periods, medium was col- 
lected and cells were washed once with buffer A (10 mM sodium phosphate, 
pH 7.0, 0.125 M NaCl), and then lysed with 0.5 ml 1% SDS. Samples were 
stored at  -20°C until use. 
MEP was immunoprecipitated from 100 #1 of medium or cell lysate with 
3 #l of MEP antiserum, as previously described (11). Immunoprecipitin was 
used to collect the antibody-antigen complexes. Immunoprecipitates were 
analyzed by SDS-PAGE on gels containing a total acrylamide concentration 
of  12.5%  (22).  Gels  were  subjected to  fluorography  using  En3Hance 
(DuPont  Co.,  Wilmington,  DE/New  England  Nuclear,  Boston,  MA). 
Where indicated, fluorographs were scanned with a  video densitometer 
(No. 620;  Bio-Rad Laboratories, Cambridge, MA). 
Isolation ofJJS-Labeled  Man-6-P-containing Proteins 
from Media 
Cation-independent Man-6-P receptor, immobilized on Immunoprecipitin, 
was used to isolate Man-6-P-containing proteins from the culture media of 
growth factor-treated cells. Immobilized receptor was prepared as previ- 
ously described (ll). Aliquots of culture media (100 #l) from biosyntheti- 
cally labeled cells were incubated with saturating amounts of immobilized 
receptor to allow binding of Man-6-P-containing proteins. Incubations were 
carried out at 4°C for 60 rain in buffer B (50 mM Tris-HCI, pH 7.5, 0.15 M 
NaC1, 0.1%  SDS,  1%  Triton X-100,  1%  sodium deoxycholate and 0.02% 
NAN3). At the end of the incubation, the samples were centrifuged and the 
pellets were washed 3 times with buffer B containing I mg/ml BSA and once 
with 0.1 M Tris, pH 6.8. Specifically bound proteins were released from the 
receptor with l0 mM Man-6-P (in 0.1 M Tris, pH 6.8). The Man-6-P releas- 
able proteins were subjected to electrophoresis as described above. 
Uptake of USl-~-Galactosidase by NIH 313 Cells 
High-affinity forms of 1251-/3-galactosidase were  isolated using  Man-6-P 
receptor immobilized on Immunoprecipitin. Immobilized receptor was pre- 
pared  as  described previously  (11). 1251-~-Galactosidase  was  incubated 
with immobilized receptor in TBS (50 mM Tris,  pH 7.2,  150 mM NaCI) 
containing 1 mg/ml BSA for 45 rain at 4°C. The Immunoprecipitin was then 
washed five times with TBS containing 1 mg/ml BSA. High affinity/3-galac- 
tosidase was eluted with 5 mM Man-6-P in the same buffer. The preparation 
was dialyzed against 50 mM sodium phosphate, pH 7.2,  150 mM NaCI be- 
fore use in the uptake experiments. 
Cells in 60-mm plates were pretreated with 15 ng/ml PDGF in serum- 
free DME containing 10 ng/ml transferrin, 4  nM sodium selenite, and  1 
mg/ml BSA for various times. The cells were then chilled on ice and treated 
for 15 rain with ice-cold 2 mM Man-6-P to remove any endogenous cell 
surface ligands. Cells were washed twice with Hepes-buffered DME (50 
mM Hepes, pH 7.2) containing 1 mg/ml BSA and twice with Hepes-buffered 
DME alone.  Prewarmed (37°C)  uptake  medium (serum-free DME plus 
1 mg/ml BSA), containing 100,000 cpm high-uptake 12Sl-/3-galactosidase/ 
plate, was added and the uptake was carried out for 30 rain at 37°C.  The 
cells were then returned to the ice bath, the medium was removed, and cells 
were washed once with Hepes-buffered  DME plus 1 mg/ml BSA, twice with 
Hepes-buffered DME, and once with Hepes-buffered saline. Cells were 
lysed with 1 ml of 1% sodium deoxycholate and radioactivity in the lysates 
was determined with a counter (Gamma 4000; Beckman Instruments, Palo 
Alto, CA). Protein concentration of the lysates was assayed according to the 
method of Lowry (25). Specific uptake via the Man-6-P receptor was deter- 
mined by subtracting uptake values obtained in the presence of 5 mM Man- 
6-P from values obtained in the absence of Man-6-P for each pretreatment 
time. 
Results 
Effect of PDGF on Secretion of Proteins by 
NIH 3T3 Cells 
When NIH 3T3 fibroblasts are treated with PDGF, there are 
both qualitative and quantitative changes  in  secreted pro- 
teins.  Previous studies  have demonstrated that PDGF in- 
duces both synthesis and secretion of MEP (13, 41), but the 
actual level of secretion relative to the total amount synthe- 
sized has  not been determined.  Fig.  1 shows  that PDGF 
treatment of NIH 3T3 cells results in secretion of most of the 
MEP made by these cells. The effects of PDGF on total pro- 
tein secretion are shown on the left, and MEP secretion is 
illustrated on the right. PDGF caused enhanced secretion of 
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NIH 3T3 cells.  Density-arrested  NIH-3T3  cells were labeled for 
18 h with 200/xCi/ml  [aSS]methionine in serum-free  DME with 
no additions (lane 1), or in the presence of 15 ng/ml PDGF (lane 
2),  10  mM  NH4Cl (lane  3),  or  PDGF  plus  NH4CI (lane  4). 
Shpwn is a fluorograph of  SDS-polyacrylamide gels of  the total pro- 
teins present in 10 #1 media (left) and immunoprecipitates of MEP 
(right) from 100/~1 media. 
a  number of proteins, but the most dramatic effect was on 
MEP. Since treatment of cells in culture with NI-LCI causes 
secretion of newly  synthesized  lysosomal hydrolases  (19), 
the percent of the total MEP that was secreted was estimated 
by comparing the amount of MEP secreted in the absence of 
NI-LCI (lanes I  and 2) to that secreted by the NI-LCl-treated 
cells (lanes 3 and 4). Control cells secreted very little (<10%) 
newly  synthesized  MEP,  whereas  in  PDGF-treated  cells 
most of the  MEP  was  secreted.  Also,  by  comparing the 
amount  of MEP  secreted  by  NI-LCl-treated control  cells 
(lane 3) and PDGF-treated cells (lane 4),  it is evident that 
PDGF caused an ,',d0-fold increase in MEP synthesis as well 
as increasing MEP secretion. 
Time Course for PDGF-Mediated Effects on MEP 
Synthesis and Secretion 
To compare time-dependent effects of PDGF on MEP secre- 
tion to effects on MEP synthesis, we determined the amount 
of time required for PDGF to affect MEP synthesis in our 
tissue culture system. As shown in Fig. 2, PDGF treatments 
of <1 h had little effect on the amount of MEP synthesized 
by NIH 3T3 cells. However, after a 2-h exposure to PDGE 
MEP synthesis was seven times higher than in control cells 
(as determined by densitometry), and leveled off at an 8-9- 
fold increase between 3 and 4  h after PDGF addition.  The 
effect of PDGF on MEP synthesis did not require the con- 
tinued presence of the growth factor; treatment of the cells 
with PDGF for as little as 30 min yielded the same increases 
in MEP synthesis at later times as those seen when PDGF 
was  present  throughout  the  entire  experiment  (data  not 
shown). 
The level of MEP secretion by the cells after various times 
of incubation with PDGF was examined next. As a means of 
estimating the total amount of MEP synthesized during the 
labeling period, we took advantage of the effects of NI-LC1 
on secretion of Man-6-P-containing lysosomal enzymes, as 
described above.  The amount of labeled MEP  secreted by 
NtLCl-treated  cells  represents  the  total  amount  of MEP 
made  during  the  labeling  period.  The  amount  of  MEP 
secreted in the absence of the amine represents the portion 
of the total which was secreted in response to the growth fac- 
tor. The validity of these assumptions has been verified by 
pulse-chase studies (data not shown). 
As shown in Fig. 3, after short treatments (0.5 or 1 h) with 
PDGE the amount of MEP synthesized (+NI-LCI lanes) re- 
mained near the control level.  However, in contrast to the 
control,  nearly  all  of  the  MEP  was  secreted  (compare 
-NH4C1  lanes with  +NILCI lanes).  After 2  h  of growth 
factor treatment,  the  cells  synthesized a  larger amount of 
MEP,  which  continued  to  be  made  after  all  of the  other 
pretreatment  times  examined  (+NI-LCI  lanes).  Although 
the level of MEP synthesis remained high from 2 to 30 h after 
PDGF addition, an elevated level of secretion was observed 
only until  18 h after the growth factor was added.  From 18 
to 30 h  following PDGF addition,  MEP secretion was dra- 
matically reduced (-NILC1 lanes) even though the amount 
synthesized  (+NI-LCI lanes)  remained  high.  Thus,  MEP 
Figure 2.  Time  course  for  PDGF  induction  of 
MEP synthesis. Density-arrested cells were treated 
with 15 ng/ml PDGF for the indicated times. Cells 
were  then  labeled  for 30  min  with  150  ttCi/ml 
[35S]methionine. At the  end of the  labeling,  the 
medium was removed and cells were washed twice 
with buffer A containing 1 mg/ml BSA, and then 
lysed with 500 #i 1% SDS. MEP was immunopre- 
cipitated from 100 #1 of the cell lysate, and the im- 
munoprecipitates were subjected to electrophore- 
sis and fluorography. 
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of PDGF on MEP secretion. Den- 
sity-arrested cells were pretreated 
with 15 ng/ml PDGF for the indi- 
cated times.  Cells  were then la- 
beled  with  150 #Ci/ml  [35S]me- 
thionine for 30 min, after which 
the label was "chased" for 5 h with 
excess  unlabeled  methionine  in 
the absence or presence of 10 mM 
NI-LCI, as indicated. Media sam- 
ples were collected, and MEP was 
immunoprecipitated from 100 #1 
of each sample. The immunopre- 
cipitates  were analyzed by elec- 
trophoresis  and fluorography. 
synthesis  and  secretion  were  regulated  independently  by 
PDGF. Similar results were obtained when cells were treated 
with fibroblast growth factor (data not shown). 
Low Level of  MEP Secretion after Prolonged PDGF 
Treatment Is not Because of  Secretion-Recapture 
It was possible that the low level of MEP secretion observed 
after long PDGF treatments (18-30 h) was because of secre- 
tion of the MEP during the early portion of the experimental 
chase period, with subsequent internalization via cell surface 
Man-6-P receptors at a later time. If  this were the case, addi- 
tion of Man-6-P to the chase medium should inhibit recap- 
ture.  As  shown  in  Fig.  4,  we found that  Man-6-P had  no 
effect on the level of MEP secreted by cells pretreated for 
26 h with PDGE indicating that MEP was not secreted and 
then recaptured during the course of the experiment. This 
finding was confirmed by pulse-chase studies in which secre- 
tion of MEP was monitored at various times during the chase 
(not shown).  At no time were high levels of MEP found to 
be secreted under these conditions. Thus, the apparent adap- 
tation  of the  cells  to  prolonged  treatment  with  PDGF  is 
related to a change in intracellular trafficking of MEP rather 
than to an alteration in endocytosis of secreted MEE 
Specificity of  MEP Secretion by PDGF-Treated Cells 
One possibility that could explain the enhanced secretion of 
MEP by PDGF-treated cells is that PDGF causes a general 
change in the lysosomal enzyme transport pathway, such that 
proteins that are normally delivered to lysosomes are secret- 
ed. If PDGF has such an effect on the transport of lysosomal 
enzymes, other lysosomal enzymes should also be secreted 
by PDGF-treated cells. Alternatively, the effects of PDGF on 
secretion of lysosomal enzymes could be selective for MEE 
To distinguish  between  these  two possibilities,  the  media 
from PDGF-treated cells were examined for other lysosom- 
al,  Man-6-P-containing proteins. 
Lysosomal enzymes that were secreted by biosynthetically 
labeled PDGF-treated cells were isolated with immobilized 
Man-6-P receptor. It was assumed that since MEP secreted 
by these cells contains  Man-6-E  other  secreted lysosomal 
enzymes  would  also  contain  the  Man-6-P  marker.  Upon 
comparing Man-6-P-containing proteins that were secreted 
in the absence of NI-LCl to those secreted in the presence of 
NI-LCI, we could determine if secretion of other lysosomal 
enzymes was affected by PDGE Fig. 5 shows that MEP was 
the only detectable Man-6-P-containing protein secreted by 
PDGF-treated cells; other major lysosomal proteins were not 
secreted in the absence of NI-LCI. Also, as indicated by the 
lanes corresponding to the NI-LCl-treated cells, the synthe- 
sis of most of the other lysosomal enzymes was not affected 
by  PDGE  The  exception  was  a  27,000-Mr  protein  whose 
synthesis (+NI-LCI lane), but not secretion (-NI-LCI lane), 
was induced after 6 h of PDGF treatment. This protein was 
identified as proliferin  (23),  also called mitogen-regulated 
protein (29), using two different antisera specific for that pro- 
tein (data not shown). 
PDGF-induced MEP Secretion Requires 
Protein Synthesis 
As a means of further defining the requirements for secretion 
of MEP upon addition of PDGF to density-arrested fibro- 
blasts, we examined the effect of protein synthesis inhibitors 
on this secretion. For the experiments described in Table I, 
cycloheximide and actinomycin D were present only during 
the chase period, so that the amount of MEP labeled during 
the pulse was the same as in cells that were not treated with 
the inhibitors.  PDGF-induced MEP secretion was dramati- 
cally inhibited (84% decrease) in the presence of cyclohexi- 
mide. Total secretion of 35S-labeled proteins was decreased 
by only 20 % under these conditions, although >90 % of all 
protein synthesis was inhibited during the chase period (data 
Figure 4. Low MEP secretion after long-term PDGF treatment  is 
not because of secretion-recapture.  NIH 3T3 ceils were pretreated 
for 26 h with or without 15 ng/ml PDGE and labeled as described 
for Fig. 3. During the chase period,  10 mM Man-6-P and 10 mM 
NH4CI were present  where  indicated.  Media samples were col- 
lected and MEP was immunoprecipitated from 100 #1 media and 
analyzed by SDS-PAGE and fluorography. 
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samples from untreated cells or cells pretreated with PDGF for 0.5 
or 6 h, labeled as described for the experiment in Fig. 3, were in- 
cubated with immobilized Man-6-P receptor in order to isolate all 
secreted  Man-6-P-containing  lysosomal  enzymes.  Proteins  that 
specifically bound to the receptor were released with 10 mM Man- 
6-P, and subjected to electrophoresis and fluorography. The differ- 
ence in the amount of MEP present in the  +NH4C! lanes for the 
no addition and 0.5 h pretreatment times is attributed to a loss of 
some of the untreated cells during the course of the experiment. 
not shown).  This indicates that cycloheximide did not have 
an adverse effect on general protein secretion, but that the 
inhibition of MEP secretion was relatively specific. Similar 
inhibition of MEP secretion was observed when puromycin 
Table I. Effect of Cycloheximide and Actinomycin D 
on MEP Secretion 
Treatment  Percent secretion* 
None  ~< 15 
PDGF  103  +  23 
PDGF  +  cycloheximide  19  +  3 
PDGF  +  actinomycin D  68  +  13 
* Percent secretion refers m the amount of MEP secreted in the absence of 
NH4CI relative to the amount secreted in the presence of 10 mM NH4CI for 
each condition. 
Density-arrested cells were pretreated with 15 ng/ml PDGF for I h and then 
pulse-labeled with [3SS]methionine as described for Fig. 3. The label was then 
"chased" for 5 h in the absence or presence of 10 mM NH4CI and in the ab- 
sence or presence of 10/zg/ml cycloheximide or actinomycin D. MEP was im- 
munoprecipitated from the media samples and analyzed by SDS-PAGE. Values 
were obtained by densitometric scanning of fluorographs, and are expressed as 
the mean 5:  I  SD obtained from three separate experiments. 
(10 #g/ml) was used to block protein synthesis. Examination 
of cell lysates from the cycloheximide-treated cells revealed 
no accumulation of the precursor form of MEP in these cells 
(data not  shown).  The site at which  degradation occurred 
was not determined. These results suggest that secretion of 
MEP is dependent on the synthesis of a protein(s) during the 
experimental chase period.  The effect of this protein(s) on 
MEP secretion is apparently short lived since it is abruptly 
lost upon addition of cycloheximide or puromycin. 
One explanation for the inhibition of MEP secretion by cy- 
cloheximide is that high levels of MEP synthesized during 
the experimental chase period are responsible for PDGF- 
induced  secretion of the  labeled  MEP.  (This  could  result 
from saturation of the transport system for MEP as suggested 
for virally transformed cells [11]). To investigate this possi- 
bility,  synthesis of MEP  mRNA during the chase was in- 
hibited with actinomycin D. We found that addition of ac- 
tinomycin D  to  the  PDGF-treated cells  at  the  end  of the 
labeling period resulted in a >90%  inhibition of MEP syn- 
thesis and 40%  inhibition of total protein synthesis during 
the 5-h chase (data not shown). However, in contrast to the 
dramatic inhibition caused by cycloheximide, PDGF-induced 
MEP secretion was only slightly affected by actinomycin D 
(35 % decrease). These results indicate that the effect is not 
because of increased synthesis of MEP but instead to some 
constitutively  synthesized  factor  whose  message  is  long- 
lived relative to that of MEP. 
Effect of  PDGF on Man-6-P Receptor-mediated 
Endocytosis 
PDGF-induced altered trafficking of MEP, a protein that is 
normally transported by Man-6-P  receptors,  suggests that 
the transport system itself may be affected in PDGF-treated 
cells. One measure of Man-6-P receptor function is the en- 
docytosis of Man-6-P-containing  ligands.  We used  [L25I]/~- 
galactosidase as a tool to investigate possible effects of PDGF 
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Figure 6.  Effect of PDGF on ['25I]~-galactosidase uptake by NIH 
3T3 cells. Density-arrested NIH 3T3 cells were either left untreated 
or were pretreated with PDGF (15 ng/ml) for 0.25, 0.5,  1, 2, or 4  h 
and  then tested  for the ability  to  uptake  [t25I]/~-galactosidase via 
Man-6-P receptors.  The data are expressed as the percent of the 
control uptake that is the amount of [t2sI]fl-galactosidase taken up 
by untreated cells.  Shown are the mean values obtained  from two 
separate determinations. 
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cells were pretreated with PDGF for various times and then 
assayed for their ability to uptake [~25I]/3-galactosidase. As 
shown in Fig. 6, after a 30-min lag, PDGF treatment resulted 
in a time-dependent increase in [t25I]/$-galactosidase uptake 
that reached a plateau at 165% of the control value by 2 h. 
Therefore, PDGF affected Man-6-P receptor function within 
a time frame similar to that of the PDGF-mediated increase 
in MEP secretion. 
Discussion 
To define mechanisms responsible for growth-related changes 
in the transport of lysosomal enzymes, and to identify possi- 
ble roles of secreted lysosomal hydrolases in growth and 
metastasis, we have been examining lysosomal protein syn- 
thesis and trafficking in NIH 3T3  fibroblasts transformed 
with an oncogenic virus or treated with growth factors. Pre- 
vious studies have shown that increased amounts of MEP are 
synthesized and secreted by mouse fibroblasts upon viral 
transformation or growth factor treatment, and it has been 
proposed that MEP overproduction alone is sufficient to ac- 
count for the enhanced secretion (11, 44). The present inves- 
tigation examines the time dependency of PDGF-induced 
synthesis and secretion of MEP by untransformed NIH 3T3 
cells, and provides evidence that MEP secretion is not a di- 
rect result of its increased synthesis as previously suggested. 
PDGF treatment of  the cells resulted in time-dependent in- 
creases in both MEP synthesis and MEP secretion. MEP 
synthesis was induced between 1 and 2 h after PDGF addi- 
tion, and remained high for at least 30 h (Figs. 2 and 3). This 
is consistent with a previous study by Scher et al. (41), which 
demonstrated that in BALB/c 3T3  cells PDGF  enhanced 
MEP synthesis within 40 min after growth factor addition, 
with a high level of synthesis continuing through 24 h. In- 
creased synthesis of MEP in response to PDGF and viral 
transformation has  been  attributed to  increased levels  of 
MEP messenger RNA (13, 18). 
PDGF-enhanced MEP secretion was found to be regulated 
independently of MEP synthesis. After short PDGF treat- 
ments (~<1 h), when MEP synthesis was still near control lev- 
els, newly synthesized MEP was secreted. After prolonged 
incubation with PDGF (>18  h) the cells secreted progres- 
sively less MEP, despite the continued high level of MEP 
synthesis. These results indicate that signals generated by 
PDGF treatment regulate intracellular trafficking of MEP 
and that this regulation is different from that responsible for 
the effects on MEP synthesis. 
The  PDGF-induced  alteration  in  MEP  trafficking was 
found to be specific, in that secretion of other lysosomal pro- 
teins was not significantly affected (Fig. 5). While this sug- 
gests the possibility that altered trafficking of MEP results 
from  specific  PDGF-induced  changes  in  MEP,  no  such 
changes have been found. MEP made by PDGF-treated NIH 
3T3 cells has the same affinity for the cation-independent 
Man-6-P receptor as MEP made by quiescent cells (our un- 
published  results).  Also,  the  MEP  made  by  resting  and 
growth factor-treated NIH cells, as well as MEP made by 
transformed NIH cells, display similar peptide maps (16, 
18). Thus,  it appears that secretion of MEP results from 
PDGF-induced alterations in the lysosomal protein transport 
system rather than from changes in MEP itself. Lysosomal 
delivery of MEP in quiescent NIH cells is mediated by the 
cation independent Man-6-P receptor, as demonstrated by 
the inhibition of lysosomal delivery of MEP when antibodies 
to this receptor are added to the culture medium (our unpub- 
lished data). Thus, the most likely target for the PDGF effect 
is the cation-independent Man-6-P receptor. 
Signals generated by PDGF could act by causing a reduc- 
tion in the total concentration of functional cation-indepen- 
dent receptors within the cell. Because of the intrinsic low 
affinity of MEP for the receptor, such a condition would be 
expected to cause selective secretion of MEP by "default; via 
the constitutive secretory pathway (11). However,  preferen- 
tial secretion of MEP was, not observed when cation-inde- 
pendent Man-6-P receptors were progressively depleted by 
treatment of cells with increasing concentrations of NI-LC1 
or receptor antibodies (our unpublished data); MEP secre- 
tion paralleled secretion of other Man-6-P-containing pro- 
teins under those conditions. Also, a direct assay of Man-6-P 
receptors revealed no differences in receptor levels between 
untreated and PDGF-treated cells (our unpublished data). 
These results indicate that a simple reduction in the total lev- 
els of cation-independent receptors is not responsible for the 
effects on MEP transport observed in PDGF-treated cells. 
An alteration in the interaction of the receptor with MEP 
might also be caused by changes in the distribution or bind- 
ing properties of the receptor, or in the rate of transit of the 
receptor or MEP through the cell. Fig. 6 shows that PDGF 
does affect Man-6-P receptor function, in that endocytosis 
via this receptor is greatly increased in PDGF-treated ceils. 
Such  an effect by PDGF is indicative of an alteration in 
receptor distribution or cycling rate. Future studies will de- 
termine whether the enhanced uptake is because of more 
receptors present at the cell surface or an increased rate of 
endocytosis of cell  surface receptors.  Increased  levels  of 
cation-independent Man-6-P receptors at the cell surface in 
response to insulin (1, 4, 5, 24, 30, 48), insulin-like growth 
factor I, insulin-like growth factor II, and epidermal growth 
factor (1) have been reported for other cell lines. Therefore, 
it is likely that the increased uptake we observed is because 
of a similar redistribution of receptors. Our data support a 
model in which PDGF alters the distribution of Man-6-P 
receptors, such that the Golgi concentration of receptors be- 
comes limiting; the receptors become saturated with high 
affinity lysosomal enzymes, and low affinity MEP is secreted 
instead of being transported to lysosomes. 
While  a  mechanism  involving  modulation  of  cation- 
independent Man-6-P receptor function is favored, we can- 
not rule out the possibility that the cation-dependent recep- 
tor, or some as yet unknown receptor or binding protein, is 
involved in PDGF-induced MEP secretion. Since lysosomal 
delivery of MEP in these cells is normally mediated by the 
cation-independent receptor, other proteins involved in MEP 
secretion would most likely act by preventing the interaction 
of MEP with the cation-independent Man-6-P receptor. 
The finding that cycloheximide dramatically inhibits PDGF- 
induced MEP secretion (Table !) suggests that protein syn- 
thesis is required to produce this effect. It appears that the 
protein(s) involved is rapidly turned over, since addition of 
cycloheximide 6 h after the PDGF also blocked subsequent 
MEP secretion (our unpublished observations). Actinomy- 
cin D, which inhibits MEP synthesis by >90%, had only a 
slight effect on MEP secretion, to the same extent as the 
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was due to a decrease in the synthesis of some protein other 
than MEP. One explanation for the cycloheximide-mediated 
inhibition of MEP secretion in PDGF treated cells is that cy- 
cloheximide decreases the synthesis of other lysosomal en- 
zymes,  resulting in a  decrease  in the occupancy of Golgi 
Man-6-P  receptors by other ligands,  thereby allowing the 
binding and lysosomal delivery of MEP.  An alternate expla- 
nation is that in response to PDGF, some short-lived protein, 
whose synthesis is inhibited by cycloheximide, directly par- 
ticipates in the diversion of MEP from the lysosomal deliv- 
ery pathway. If this is the case, the identification and charac- 
terization of such a protein will be critical to further studies 
on  the  mechanisms  of regulated  MEP  secretion.  PDGF- 
induced MEP mRNA synthesis also requires protein synthe- 
sis  (13,  36).  Whether  the  same  or  different  proteins  are 
responsible for these two events remains to be determined. 
Although the evidence accumulated thus far is correlative, 
it does appear that there is a link between cell growth and 
lysosomal enzyme secretion.  The specificity  and time de- 
pendency of PDGF-induced MEP secretion suggests that this 
is a highly regulated process.  The role of secreted MEP in 
the growth process is unknown, but some conclusions can 
be drawn from the observations described above. First, MEP 
secretion is stimulated by growth factors such as PDGF and 
fibroblast growth factor,  which render cells competent (33) 
to enter into mitosis, suggesting that MEP secretion is related 
to the cells' acquisition of"competence." Furthermore, MEP 
secretion was maximal after 6-10 h, whereas DNA synthesis 
was not observed until 12 h after  PDGF addition and con- 
tinued to  rise  through  18  h  (our unpublished results),  at 
which time MEP secretion was decreased. Therefore, MEP 
may be needed to prepare the cells or extracellular milieu for 
mitosis. Since MEP is a cysteine protease, it is possible that 
secreted  MEP hydrolyzes extracellular matrix components 
(14) or proteins on the cell surface. Indeed, purified MEP has 
been shown to degrade collagen, fibronectin, and laminin in 
vitro (14). Further studies investigating these and other pos- 
sibilities should provide definitive proof of MEP's function 
in cell growth. 
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